Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva

It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).